167 related articles for article (PubMed ID: 37726935)
1. Remission of severe myasthenia gravis after autologous stem cell transplantation.
Schlatter MI; Yandamuri SS; O'Connor KC; Nowak RJ; Pham MC; Obaid AH; Redman C; Provost M; McSweeney PA; Pearlman ML; Tees MT; Bowen JD; Nash RA; Georges GE
Ann Clin Transl Neurol; 2023 Nov; 10(11):2105-2113. PubMed ID: 37726935
[TBL] [Abstract][Full Text] [Related]
2. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report.
Sossa Melo CL; Peña AM; Salazar LA; Jiménez SI; Gómez ED; Chalela CM; Ayala-Castillo M; Peña IM
Neuromuscul Disord; 2019 Feb; 29(2):142-145. PubMed ID: 30639064
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies.
Beland B; Hahn C; Jamani K; Chhibber S; White C; Atkins H; Storek J
Muscle Nerve; 2023 Feb; 67(2):154-157. PubMed ID: 36527328
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.
Bryant A; Atkins H; Pringle CE; Allan D; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Hopkins H; Huebsch L; McDiarmid S; Sabloff M; Sheppard D; Tay J; Bredeson C
JAMA Neurol; 2016 Jun; 73(6):652-8. PubMed ID: 27043206
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
7. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
8. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
[TBL] [Abstract][Full Text] [Related]
9. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis - a case report.
Håkansson I; Sandstedt A; Lundin F; Askmark H; Pirskanen R; Carlson K; Piehl F; Hägglund H
Neuromuscul Disord; 2017 Jan; 27(1):90-93. PubMed ID: 27863874
[TBL] [Abstract][Full Text] [Related]
10. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Nash RA; Bowen JD; McSweeney PA; Pavletic SZ; Maravilla KR; Park MS; Storek J; Sullivan KM; Al-Omaishi J; Corboy JR; DiPersio J; Georges GE; Gooley TA; Holmberg LA; LeMaistre CF; Ryan K; Openshaw H; Sunderhaus J; Storb R; Zunt J; Kraft GH
Blood; 2003 Oct; 102(7):2364-72. PubMed ID: 12763935
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
12. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
Nash RA; McSweeney PA; Crofford LJ; Abidi M; Chen CS; Godwin JD; Gooley TA; Holmberg L; Henstorf G; LeMaistre CF; Mayes MD; McDonagh KT; McLaughlin B; Molitor JA; Nelson JL; Shulman H; Storb R; Viganego F; Wener MH; Seibold JR; Sullivan KM; Furst DE
Blood; 2007 Aug; 110(4):1388-96. PubMed ID: 17452515
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T;
Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278
[TBL] [Abstract][Full Text] [Related]
15. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.
De Rosa A; Fornili M; Maestri Tassoni M; Guida M; Baglietto L; Petrucci L; Chella A; Melfi F; Lucchi M; Ricciardi R
Thorac Cancer; 2021 Jan; 12(1):106-113. PubMed ID: 33142021
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis.
Kim KC; Lee IH; Choi JH; Oh MR; Ahn MJ; Kim SY
J Korean Med Sci; 2002 Feb; 17(1):129-32. PubMed ID: 11850603
[TBL] [Abstract][Full Text] [Related]
17. Do associated auto-antibodies influence the outcome of myasthenia gravis after thymectomy?
Keijzers M; Damoiseaux J; Vigneron A; Bodart N; Kessels A; Dingemans AM; Hochstenbag M; Maessen J; De Baets M
Autoimmunity; 2015; 48(8):552-5. PubMed ID: 26226195
[TBL] [Abstract][Full Text] [Related]
18. Robotic-Extended Rethymectomy for Refractory Myasthenia Gravis: A Case Series.
Li F; Li Z; Takahashi R; Ioannis A; Ismail M; Meisel A; Rueckert JC
Semin Thorac Cardiovasc Surg; 2020 Autumn; 32(3):593-602. PubMed ID: 31682904
[TBL] [Abstract][Full Text] [Related]
19. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravis.
Marcuse F; Hoeijmakers JGJ; Hochstenbag M; Hamid MA; Keijzers M; Mané-Damas M; Martinez-Martinez P; Verschuuren J; Kuks J; Beekman R; van der Kooi AJ; van Doorn P; van Es M; Maessen JJG; De Baets MHV
Neuromuscul Disord; 2023 May; 33(5):417-424. PubMed ID: 37037051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
